Copyright Reports & Markets. All rights reserved.

Global Glucose Dependent Insulinotropic Receptor Market Insights, Forecast to 2025

Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Glucose Dependent Insulinotropic Receptor Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Glucose Dependent Insulinotropic Receptor Market Size Growth Rate by Product
      • 1.4.2 DA-1241
      • 1.4.3 GSK-2041706
      • 1.4.4 HD-0471042
      • 1.4.5 HD-0471953
      • 1.4.6 HOB-047
      • 1.4.7 MBX-2982
      • 1.4.8 Others
    • 1.5 Market by End User
      • 1.5.1 Global Glucose Dependent Insulinotropic Receptor Market Size Growth Rate by End User
      • 1.5.2 Type 2 Diabetes
      • 1.5.3 Obesity
      • 1.5.4 Chronic Obstructive Pulmonary Disease (COPD)
      • 1.5.5 Dyslipidemia
      • 1.5.6 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Glucose Dependent Insulinotropic Receptor Market Size
      • 2.1.1 Global Glucose Dependent Insulinotropic Receptor Revenue 2014-2025
      • 2.1.2 Global Glucose Dependent Insulinotropic Receptor Sales 2014-2025
    • 2.2 Glucose Dependent Insulinotropic Receptor Growth Rate by Regions
      • 2.2.1 Global Glucose Dependent Insulinotropic Receptor Sales by Regions
      • 2.2.2 Global Glucose Dependent Insulinotropic Receptor Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Glucose Dependent Insulinotropic Receptor Sales by Manufacturers
      • 3.1.1 Glucose Dependent Insulinotropic Receptor Sales by Manufacturers
      • 3.1.2 Glucose Dependent Insulinotropic Receptor Sales Market Share by Manufacturers
      • 3.1.3 Global Glucose Dependent Insulinotropic Receptor Market Concentration Ratio (CR5 and HHI)
    • 3.2 Glucose Dependent Insulinotropic Receptor Revenue by Manufacturers
      • 3.2.1 Glucose Dependent Insulinotropic Receptor Revenue by Manufacturers (2014-2019)
      • 3.2.2 Glucose Dependent Insulinotropic Receptor Revenue Share by Manufacturers (2014-2019)
    • 3.3 Glucose Dependent Insulinotropic Receptor Price by Manufacturers
    • 3.4 Glucose Dependent Insulinotropic Receptor Manufacturing Base Distribution, Product Types
      • 3.4.1 Glucose Dependent Insulinotropic Receptor Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Glucose Dependent Insulinotropic Receptor Product Type
      • 3.4.3 Date of International Manufacturers Enter into Glucose Dependent Insulinotropic Receptor Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Glucose Dependent Insulinotropic Receptor Sales by Product
    • 4.2 Global Glucose Dependent Insulinotropic Receptor Revenue by Product
    • 4.3 Glucose Dependent Insulinotropic Receptor Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Glucose Dependent Insulinotropic Receptor Breakdown Data by End User

    6 North America

    • 6.1 North America Glucose Dependent Insulinotropic Receptor by Countries
      • 6.1.1 North America Glucose Dependent Insulinotropic Receptor Sales by Countries
      • 6.1.2 North America Glucose Dependent Insulinotropic Receptor Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Glucose Dependent Insulinotropic Receptor by Product
    • 6.3 North America Glucose Dependent Insulinotropic Receptor by End User

    7 Europe

    • 7.1 Europe Glucose Dependent Insulinotropic Receptor by Countries
      • 7.1.1 Europe Glucose Dependent Insulinotropic Receptor Sales by Countries
      • 7.1.2 Europe Glucose Dependent Insulinotropic Receptor Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Glucose Dependent Insulinotropic Receptor by Product
    • 7.3 Europe Glucose Dependent Insulinotropic Receptor by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Glucose Dependent Insulinotropic Receptor by Countries
      • 8.1.1 Asia Pacific Glucose Dependent Insulinotropic Receptor Sales by Countries
      • 8.1.2 Asia Pacific Glucose Dependent Insulinotropic Receptor Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Glucose Dependent Insulinotropic Receptor by Product
    • 8.3 Asia Pacific Glucose Dependent Insulinotropic Receptor by End User

    9 Central & South America

    • 9.1 Central & South America Glucose Dependent Insulinotropic Receptor by Countries
      • 9.1.1 Central & South America Glucose Dependent Insulinotropic Receptor Sales by Countries
      • 9.1.2 Central & South America Glucose Dependent Insulinotropic Receptor Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Glucose Dependent Insulinotropic Receptor by Product
    • 9.3 Central & South America Glucose Dependent Insulinotropic Receptor by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Glucose Dependent Insulinotropic Receptor by Countries
      • 10.1.1 Middle East and Africa Glucose Dependent Insulinotropic Receptor Sales by Countries
      • 10.1.2 Middle East and Africa Glucose Dependent Insulinotropic Receptor Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Glucose Dependent Insulinotropic Receptor by Product
    • 10.3 Middle East and Africa Glucose Dependent Insulinotropic Receptor by End User

    11 Company Profiles

    • 11.1 Amgen Inc
      • 11.1.1 Amgen Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Amgen Inc Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Amgen Inc Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.1.5 Amgen Inc Recent Development
    • 11.2 Arena Pharmaceuticals Inc
      • 11.2.1 Arena Pharmaceuticals Inc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.2.5 Arena Pharmaceuticals Inc Recent Development
    • 11.3 CymaBay Therapeutics Inc
      • 11.3.1 CymaBay Therapeutics Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.3.5 CymaBay Therapeutics Inc Recent Development
    • 11.4 Dong-A Socio Holdings Co Ltd
      • 11.4.1 Dong-A Socio Holdings Co Ltd Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.4.5 Dong-A Socio Holdings Co Ltd Recent Development
    • 11.5 F. Hoffmann-La Roche Ltd
      • 11.5.1 F. Hoffmann-La Roche Ltd Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.5.5 F. Hoffmann-La Roche Ltd Recent Development
    • 11.6 GlaxoSmithKline Plc
      • 11.6.1 GlaxoSmithKline Plc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.6.5 GlaxoSmithKline Plc Recent Development
    • 11.7 Hyundai Pharmaceutical Co Ltd
      • 11.7.1 Hyundai Pharmaceutical Co Ltd Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.7.5 Hyundai Pharmaceutical Co Ltd Recent Development
    • 11.8 Kowa Co Ltd
      • 11.8.1 Kowa Co Ltd Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.8.5 Kowa Co Ltd Recent Development
    • 11.9 Merck & Co Inc
      • 11.9.1 Merck & Co Inc Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.9.5 Merck & Co Inc Recent Development
    • 11.10 Novartis AG
      • 11.10.1 Novartis AG Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Novartis AG Glucose Dependent Insulinotropic Receptor Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Novartis AG Glucose Dependent Insulinotropic Receptor Products Offered
      • 11.10.5 Novartis AG Recent Development
    • 11.11 Taisho Pharmaceutical Holdings Co Ltd
    • 11.12 Takeda Pharmaceutical Co Ltd
    • 11.13 Yuhan Corp

    12 Future Forecast

    • 12.1 Glucose Dependent Insulinotropic Receptor Market Forecast by Regions
      • 12.1.1 Global Glucose Dependent Insulinotropic Receptor Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Glucose Dependent Insulinotropic Receptor Revenue Forecast by Regions 2019-2025
    • 12.2 Glucose Dependent Insulinotropic Receptor Market Forecast by Product
      • 12.2.1 Global Glucose Dependent Insulinotropic Receptor Sales Forecast by Product 2019-2025
      • 12.2.2 Global Glucose Dependent Insulinotropic Receptor Revenue Forecast by Product 2019-2025
    • 12.3 Glucose Dependent Insulinotropic Receptor Market Forecast by End User
    • 12.4 North America Glucose Dependent Insulinotropic Receptor Forecast
    • 12.5 Europe Glucose Dependent Insulinotropic Receptor Forecast
    • 12.6 Asia Pacific Glucose Dependent Insulinotropic Receptor Forecast
    • 12.7 Central & South America Glucose Dependent Insulinotropic Receptor Forecast
    • 12.8 Middle East and Africa Glucose Dependent Insulinotropic Receptor Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Glucose Dependent Insulinotropic Receptor Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Glucose Dependent Insulinotropic Receptor market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Glucose Dependent Insulinotropic Receptor market based on company, product type, end user and key regions.

      This report studies the global market size of Glucose Dependent Insulinotropic Receptor in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Glucose Dependent Insulinotropic Receptor in these regions.
      This research report categorizes the global Glucose Dependent Insulinotropic Receptor market by top players/brands, region, type and end user. This report also studies the global Glucose Dependent Insulinotropic Receptor market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Amgen Inc
      Arena Pharmaceuticals Inc
      CymaBay Therapeutics Inc
      Dong-A Socio Holdings Co Ltd
      F. Hoffmann-La Roche Ltd
      GlaxoSmithKline Plc
      Hyundai Pharmaceutical Co Ltd
      Kowa Co Ltd
      Merck & Co Inc
      Novartis AG
      Taisho Pharmaceutical Holdings Co Ltd
      Takeda Pharmaceutical Co Ltd
      Yuhan Corp

      Market size by Product
      DA-1241
      GSK-2041706
      HD-0471042
      HD-0471953
      HOB-047
      MBX-2982
      Others
      Market size by End User
      Type 2 Diabetes
      Obesity
      Chronic Obstructive Pulmonary Disease (COPD)
      Dyslipidemia
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Glucose Dependent Insulinotropic Receptor market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Glucose Dependent Insulinotropic Receptor market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Glucose Dependent Insulinotropic Receptor companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Glucose Dependent Insulinotropic Receptor submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Glucose Dependent Insulinotropic Receptor are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Glucose Dependent Insulinotropic Receptor market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now